Clinical Trial Update: Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib

View source ↗

Summary

A clinical trial investigating biomarkers in pulmonary arterial hypertension treated with nilotinib has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: The Cleveland Clinic | Conditions: PAH | Status: WITHDRAWN